{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:34:58Z","timestamp":1790764498297,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T00:00:00Z","timestamp":1480291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T00:00:00Z","timestamp":1480291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1038\/leu.2016.358","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T07:44:17Z","timestamp":1480319057000},"page":"1570-1581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment"],"prefix":"10.1038","volume":"31","author":[{"given":"F","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M H","family":"Bashari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Tonon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Malvestiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Vallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Jarahian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Seckinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Bakiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C R","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Glimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Sattler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E F","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Podar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"key":"BFleu2016358_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/nyas.13038","volume":"1364","author":"H Fairfield","year":"2016","unstructured":"Fairfield H, Falank C, Avery L, Reagan MR . Multiple myeloma in the marrow: pathogenesis and treatments. Ann NY Acad Sci 2016; 1364: 32\u201351.","journal-title":"Ann NY Acad Sci"},{"key":"BFleu2016358_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/leu.2008.259","volume":"23","author":"K Podar","year":"2009","unstructured":"Podar K, Chauhan D, Anderson KC . Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009; 23: 10\u201324.","journal-title":"Leukemia"},{"key":"BFleu2016358_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrc2460","volume":"8","author":"A Eych\u00e8ne","year":"2008","unstructured":"Eych\u00e8ne A, Rocques N, Pouponnot C . A new MAFia in cancer. Nat Rev Cancer 2008; 8: 683\u2013693.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2016358_CR4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1126\/science.2541502","volume":"244","author":"LR Bernstein","year":"1989","unstructured":"Bernstein LR, Colburn NH . AP1\/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science 1989; 244: 566\u2013569.","journal-title":"Science"},{"key":"BFleu2016358_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nrc1209","volume":"3","author":"R Eferl","year":"2003","unstructured":"Eferl R, Wagner EF . AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3: 859\u2013868.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2016358_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2174\/156800907780809723","volume":"7","author":"CP Matthews","year":"2007","unstructured":"Matthews CP, Colburn NH, Young MR . AP-1 a target for cancer prevention. Curr Cancer Drug Targets 2007; 7: 317\u2013324.","journal-title":"Curr Cancer Drug Targets"},{"key":"BFleu2016358_CR7","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1084\/jem.20130795","volume":"211","author":"B Gr\u00f6tsch","year":"2014","unstructured":"Gr\u00f6tsch B, Brachs S, Lang C, Luther J, Derer A, Schl\u00f6tzer-Schrehardt U et al. The AP-1 transcription factor Fra1 inhibits follicular B cell differentiation into plasma cells. J Exp Med 2014; 211: 2199\u20132212.","journal-title":"J Exp Med"},{"key":"BFleu2016358_CR8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nrrheum.2010.133","volume":"6","author":"SA Krum","year":"2010","unstructured":"Krum SA, Chang J, Miranda-Carboni G, Wang C-Y . Novel functions for NF\u03baB: inhibition of bone formation. Nat Rev Rheumatol 2010; 6: 607\u2013611.","journal-title":"Nat Rev Rheumatol"},{"key":"BFleu2016358_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1600-065X.2012.01113.x","volume":"247","author":"NS De Silva","year":"2012","unstructured":"De Silva NS, Simonetti G, Heise N, Klein U . The diverse roles of IRF4 in late germinal center B-cell differentiation. Immunol Rev 2012; 247: 73\u201392.","journal-title":"Immunol Rev"},{"key":"BFleu2016358_CR10","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood.V92.9.3025","volume":"92","author":"M Chesi","year":"1998","unstructured":"Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL . The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH\/MMSET hybrid transcripts. Blood 1998; 92: 3025\u20133034.","journal-title":"Blood"},{"key":"BFleu2016358_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1535-6108(04)00019-4","volume":"5","author":"EM Hurt","year":"2004","unstructured":"Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5: 191\u2013199.","journal-title":"Cancer Cell"},{"key":"BFleu2016358_CR12","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1182\/blood-2010-04-278788","volume":"117","author":"CM Annunziata","year":"2011","unstructured":"Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2011; 117: 2396\u20132404.","journal-title":"Blood"},{"key":"BFleu2016358_CR13","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1158\/0008-5472.CAN-06-1863","volume":"67","author":"K Podar","year":"2007","unstructured":"Podar K, Raab MS, Tonon G, Sattler M, Baril\u00e0 D, Zhang J et al. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer Res 2007; 67: 1680\u20131688.","journal-title":"Cancer Res"},{"key":"BFleu2016358_CR14","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.canlet.2013.09.042","volume":"343","author":"F Fan","year":"2014","unstructured":"Fan F, Tonon G, Bashari MH, Vallet S, Antonini E, Goldschmidt H et al. Targeting Mcl-1 for multiple myeloma (MM) therapy: Drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation. Cancer Lett 2014; 343: 286\u2013294.","journal-title":"Cancer Lett"},{"key":"BFleu2016358_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/gcc.20668","volume":"48","author":"L Agnelli","year":"2009","unstructured":"Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer 2009; 48: 603\u2013614.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFleu2016358_CR16","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007; 109: 1692\u20131700.","journal-title":"Blood"},{"key":"BFleu2016358_CR17","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.4049\/jimmunol.169.4.1922","volume":"169","author":"FH Vasanwala","year":"2002","unstructured":"Vasanwala FH, Kusam S, Toney LM, Dent AL . Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J Immunol 2002; 169: 1922\u20131929.","journal-title":"J Immunol"},{"key":"BFleu2016358_CR18","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1093\/emboj\/19.9.2056","volume":"19","author":"L Bakiri","year":"2000","unstructured":"Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M . Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J 2000; 19: 2056\u20132068.","journal-title":"EMBO J"},{"key":"BFleu2016358_CR19","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ng0506-500","volume":"38","author":"M Reich","year":"2006","unstructured":"Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP . GenePattern 2.0. Nat Genet 2006; 38: 500\u2013501.","journal-title":"Nat Genet"},{"key":"BFleu2016358_CR20","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545\u201315550.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2016358_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrd3870","volume":"12","author":"DW McMillin","year":"2013","unstructured":"McMillin DW, Negri JM, Mitsiades CS . The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 2013; 12: 217\u2013228.","journal-title":"Nat Rev Drug Discov"},{"key":"BFleu2016358_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/332083a0","volume":"332","author":"M Kawano","year":"1988","unstructured":"Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K et al. Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas. Nature 1988; 332: 83\u201385.","journal-title":"Nature"},{"key":"BFleu2016358_CR23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V85.4.863.bloodjournal854863","volume":"85","author":"B Klein","year":"1995","unstructured":"Klein B, Zhang XG, Lu ZY, Bataille R . Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863\u2013872.","journal-title":"Blood"},{"key":"BFleu2016358_CR24","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","volume":"108","author":"N Giuliani","year":"2006","unstructured":"Giuliani N, Rizzoli V, Roodman GD . Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006; 108: 3992\u20133996.","journal-title":"Blood"},{"key":"BFleu2016358_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0301-472X(03)00023-7","volume":"31","author":"S Greenstein","year":"2003","unstructured":"Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol 2003; 31: 271\u2013282.","journal-title":"Exp Hematol"},{"key":"BFleu2016358_CR26","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1182\/blood-2003-04-1048","volume":"103","author":"K Brocke-Heidrich","year":"2004","unstructured":"Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, Henze C, L\u00f6ffler D, Koczan D et al. Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood 2004; 103: 242\u2013251.","journal-title":"Blood"},{"key":"BFleu2016358_CR27","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1182\/blood-2007-02-071258","volume":"110","author":"PB Staber","year":"2007","unstructured":"Staber PB, Vesely P, Haq N, Ott RG, Funato K, Bambach I et al. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1\/2 and JunB translation via mTOR signaling. Blood 2007; 110: 3374\u20133383.","journal-title":"Blood"},{"key":"BFleu2016358_CR28","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1093\/emboj\/cdf389","volume":"21","author":"S Mathas","year":"2002","unstructured":"Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002; 21: 4104\u20134113.","journal-title":"EMBO J"},{"key":"BFleu2016358_CR29","doi-asserted-by":"publisher","first-page":"7628","DOI":"10.1158\/0008-5472.CAN-05-0925","volume":"65","author":"M Watanabe","year":"2005","unstructured":"Watanabe M, Sasaki M, Itoh K, Higashihara M, Umezawa K, Kadin ME et al. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1\/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res 2005; 65: 7628\u20137634.","journal-title":"Cancer Res"},{"key":"BFleu2016358_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ajpath.2011.10.007","volume":"180","author":"M Watanabe","year":"2012","unstructured":"Watanabe M, Itoh K, Togano T, Kadin ME, Watanabe T, Higashihara M et al. Ets-1 activates overexpression of JunB and CD30 in Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma. Am J Pathol 2012; 180: 831\u2013838.","journal-title":"Am J Pathol"},{"key":"BFleu2016358_CR31","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1038\/bcj.2013.60","volume":"3","author":"L Lod\u00e9","year":"2013","unstructured":"Lod\u00e9 L, Moreau P, M\u00e9nard A, Godon C, Touzeau C, Amiot M et al. Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease. Blood Cancer J 2013; 3: e163.","journal-title":"Blood Cancer J"},{"key":"BFleu2016358_CR32","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/sj.leu.2402832","volume":"17","author":"SCE Bolick","year":"2003","unstructured":"Bolick SCE, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD et al. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia 2003; 17: 451\u2013457.","journal-title":"Leukemia"},{"key":"BFleu2016358_CR33","doi-asserted-by":"publisher","first-page":"e0143847","DOI":"10.1371\/journal.pone.0143847","volume":"10","author":"R Suzuki","year":"2015","unstructured":"Suzuki R, Kikuchi S, Harada T, Mimura N, Minami J, Ohguchi H et al. Combination of a Selective HSP90\u03b1\/\u03b2 Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS One 2015; 10: e0143847.","journal-title":"PLoS One"},{"key":"BFleu2016358_CR34","doi-asserted-by":"publisher","first-page":"E131","DOI":"10.1038\/ncb0502-e131","volume":"4","author":"E Shaulian","year":"2002","unstructured":"Shaulian E, Karin M . AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131\u2013E136.","journal-title":"Nat Cell Biol"},{"key":"BFleu2016358_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0092-8674(01)00188-X","volume":"104","author":"E Passegu\u00e9","year":"2001","unstructured":"Passegu\u00e9 E, Jochum W, Schorpp-Kistner M, M\u00f6hle-Steinlein U, Wagner EF . Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell 2001; 104: 21\u201332.","journal-title":"Cell"},{"key":"BFleu2016358_CR36","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1038\/sj.onc.1210285","volume":"26","author":"RG Ott","year":"2007","unstructured":"Ott RG, Simma O, Kollmann K, Weisz E, Zebedin EM, Schorpp-Kistner M et al. JunB is a gatekeeper for B-lymphoid leukemia. Oncogene 2007; 26: 4863\u20134871.","journal-title":"Oncogene"},{"key":"BFleu2016358_CR37","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1038\/onc.2011.475","volume":"31","author":"T Kanno","year":"2012","unstructured":"Kanno T, Kamba T, Yamasaki T, Shibasaki N, Saito R, Terada N et al. JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma. Oncogene 2012; 31: 3098\u20133110.","journal-title":"Oncogene"},{"key":"BFleu2016358_CR38","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/modpathol.3800419","volume":"18","author":"GZ Rassidakis","year":"2005","unstructured":"Rassidakis GZ, Thomaides A, Atwell C, Ford R, Jones D, Claret F-X et al. JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol 2005; 18: 1365\u20131370.","journal-title":"Mod Pathol"},{"key":"BFleu2016358_CR39","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1182\/blood-2002-08-2434","volume":"101","author":"X Mao","year":"2003","unstructured":"Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker SJ . Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 2003; 101: 1513\u20131519.","journal-title":"Blood"},{"key":"BFleu2016358_CR40","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1365-2133.2004.06106.x","volume":"151","author":"X Mao","year":"2004","unstructured":"Mao X, Orchard G, Lillington DM, Child FJ, Vonderheid EC, Nowell PC et al. BCL2 and JUNB abnormalities in primary cutaneous lymphomas. Br J Dermatol 2004; 151: 546\u2013556.","journal-title":"Br J Dermatol"},{"key":"BFleu2016358_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0304-3835(95)03817-G","volume":"93","author":"KB Choo","year":"1995","unstructured":"Choo KB, Huang CJ, Chen CM, Han CP, Au LC . Jun-B oncogene aberrations in cervical cancer cell lines. Cancer Lett 1995; 93: 249\u2013253.","journal-title":"Cancer Lett"},{"key":"BFleu2016358_CR42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s004320100255","volume":"127","author":"AM Bamberger","year":"2001","unstructured":"Bamberger AM, Milde-Langosch K, R\u00f6ssing E, Goemann C, L\u00f6ning T . Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. J Cancer Res Clin Oncol 2001; 127: 545\u2013550.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFleu2016358_CR43","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/carcin\/21.7.1313","volume":"21","author":"H Wang","year":"2000","unstructured":"Wang H, Birkenbach M, Hart J . Expression of Jun family members in human colorectal adenocarcinoma. Carcinogenesis 2000; 21: 1313\u20131317.","journal-title":"Carcinogenesis"},{"key":"BFleu2016358_CR44","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/0092-8674(88)90147-X","volume":"55","author":"TD Halazonetis","year":"1988","unstructured":"Halazonetis TD, Georgopoulos K, Greenberg ME, Leder P . c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell 1988; 55: 917\u2013924.","journal-title":"Cell"},{"key":"BFleu2016358_CR45","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/0092-8674(87)90611-8","volume":"49","author":"P Angel","year":"1987","unstructured":"Angel P, Imagawa M, Chiu R, Stein B, Imbra RJ, Rahmsdorf HJ et al. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 1987; 49: 729\u2013739.","journal-title":"Cell"},{"key":"BFleu2016358_CR46","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1038\/sj.onc.1204385","volume":"20","author":"Y Chinenov","year":"2001","unstructured":"Chinenov Y, Kerppola TK . Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 2001; 20: 2438\u20132452.","journal-title":"Oncogene"},{"key":"BFleu2016358_CR47","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1038\/sj.onc.1204386","volume":"20","author":"F Maci\u00e1n","year":"2001","unstructured":"Maci\u00e1n F, L\u00f3pez-Rodr\u00edguez C, Rao A . Partners in transcription: NFAT and AP-1. Oncogene 2001; 20: 2476\u20132489.","journal-title":"Oncogene"},{"key":"BFleu2016358_CR48","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1038\/sj.onc.1204239","volume":"20","author":"H van Dam","year":"2001","unstructured":"van Dam H, Castellazzi M . Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene 2001; 20: 2453\u20132464.","journal-title":"Oncogene"},{"key":"BFleu2016358_CR49","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/nature12688","volume":"504","author":"CM Johannessen","year":"2013","unstructured":"Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 2013; 504: 138\u2013142.","journal-title":"Nature"},{"key":"BFleu2016358_CR50","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1182\/blood-2003-05-1417","volume":"102","author":"D Chauhan","year":"2003","unstructured":"Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N et al. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood 2003; 102: 3379\u20133386.","journal-title":"Blood"},{"key":"BFleu2016358_CR51","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","volume":"123","author":"Z Tian","year":"2014","unstructured":"Tian Z, D\u2019Arcy P, Wang X, Ray A, Tai Y-T, Hu Y et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 2014; 123: 706\u2013716.","journal-title":"Blood"},{"key":"BFleu2016358_CR52","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","volume":"22","author":"D Chauhan","year":"2012","unstructured":"Chauhan D, Tian Z, Nicholson B, Kumar KGS, Zhou B, Carrasco R et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 2012; 22: 345\u2013358.","journal-title":"Cancer Cell"},{"key":"BFleu2016358_CR53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.trecan.2015.07.001","volume":"1","author":"AS Bhagwat","year":"2015","unstructured":"Bhagwat AS, Vakoc CR . Targeting transcription factors in cancer. Trends Cancer 2015; 1: 53\u201365.","journal-title":"Trends Cancer"},{"issue":"Suppl 1","key":"BFleu2016358_CR54","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/ijlh.12360","volume":"37","author":"M Chesi","year":"2015","unstructured":"Chesi M, Bergsagel PL . Advances in the pathogenesis and diagnosis of multiple myeloma. Int J Lab Hematol 2015; 37 (Suppl 1): 108\u2013114.","journal-title":"Int J Lab Hematol"},{"key":"BFleu2016358_CR55","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/01.cco.0000432528.88101.1a","volume":"25","author":"JE Yeh","year":"2013","unstructured":"Yeh JE, Toniolo PA, Frank DA . Targeting transcription factors: promising new strategies for cancer therapy. Curr Opin Oncol 2013; 25: 652\u2013658.","journal-title":"Curr Opin Oncol"},{"key":"BFleu2016358_CR56","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904\u2013917.","journal-title":"Cell"},{"key":"BFleu2016358_CR57","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1078-0432.CCR-13-1950","volume":"20","author":"R Ria","year":"2014","unstructured":"Ria R, Catacchio I, Berardi S, De Luisi A, Caivano A, Piccoli C et al. HIF-1\u03b1 of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. Clin Cancer Res 2014; 20: 847\u2013858.","journal-title":"Clin Cancer Res"},{"key":"BFleu2016358_CR58","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.trsl.2014.12.001","volume":"165","author":"E Borsi","year":"2015","unstructured":"Borsi E, Terragna C, Brioli A, Tacchetti P, Martello M, Cavo M . Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma. Transl Res 2015; 165: 641\u2013650.","journal-title":"Transl Res"},{"key":"BFleu2016358_CR59","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1158\/1078-0432.CCR-11-1036","volume":"17","author":"M Fulciniti","year":"2011","unstructured":"Fulciniti M, Amin S, Nanjappa P, Rodig S, Prabhala R, Li C et al. Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res 2011; 17: 6500\u20136509.","journal-title":"Clin Cancer Res"},{"key":"BFleu2016358_CR60","doi-asserted-by":"publisher","first-page":"6930","DOI":"10.1021\/jm5004733","volume":"57","author":"N Ye","year":"2014","unstructured":"Ye N, Ding Y, Wild C, Shen Q, Zhou J . Small molecule inhibitors targeting activator protein 1 (AP-1). J Med Chem 2014; 57: 6930\u20136948.","journal-title":"J Med Chem"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2016358.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016358","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2016.358","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016358.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:30:12Z","timestamp":1648744212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,28]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["BFleu2016358"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.358","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,28]]},"assertion":[{"value":"31 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}